Explore the CVOT study for RYBELSUS PIONEER 6: cardiovascular safety 6,7 Study design: In a double-blind trial, 3183 adult patients with inadequately controlled type 2 diabetes at high CV risk (50 years of age with CVD or CKD, or 60 with at least 1 CV risk factor) were randomized to RYBELSUS 14 mg (n=1591) or placebo (n=1592), both once daily and in addition to standard of care for a median observation time of 16 months
Seizure activity results in calcium- and mitochondria-independent ROS production via NADPH and xanthine oxidase activation
18.2%) suggests that in a general obesity population without additional comorbidities, tolerability is better
Graabk T, Nguyen NT, Srensen MS, Lundby C
Each ingredient is clinically dosed for real results: brighter skin in 30-60 days, reduced spots, smoother texture, and boosted elasticity